TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01415778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet
Study: NCT01148095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Oral, single, daily, 11 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03968549

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
Study: NCT03262012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI (PT010)
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009)
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbohaler® Inhalation Powder
Description: Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Study: NCT02294812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training.
Study: NCT00925769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Escalating doses of 5/10mg/kg q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: Escalating doses of 500/650/750/900mg/m2 bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Escalating doses of 100/150mg daily
Study: NCT00683293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Hysterectomy
Description: Removal of uterus via standard laparoscopic techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted (Da Vinci®) laparoscopic hysterectomy
Description: Removal of uterus by robot-assisted laparoscopic technique
Study: NCT03380819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genome sequencing
Description: Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
Study: NCT01954680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGFLEX-skill building levels
Description: COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGFLEX-control condition
Description: In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
Study: NCT02684344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin may have prophylactic properties against post-operative urinary retention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education about signs and symptoms of urinary retention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education about signs and symptoms of urinary retention
Study: NCT00827853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty balloon
Description: Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoplasty balloon
Description: Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
Study: NCT03732443

Intervention type: DIAGNOSTIC_TEST
Intervention: FAM-CAM
Description: Family Confusion Assessment Method
Study: NCT01434693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03157856

Intervention type: OTHER
Intervention: Fluorescence assessment
Description: All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
Study: NCT03639311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered CAB LA (600 mg) Q2M, as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered CAB LA (600 mg) Q2M, as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: Administered RPV LA (900 mg), Q2M, as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: Administered RPV LA (900 mg), Q2M, as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
Study: NCT04212949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection
Description: An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection
Description: An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)
Study: NCT03262688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl collagen-matrix implant
Description: Placement of the bupivacaine collagen-matrix in the surgical site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl infiltration
Description: Infiltration of the surgical site
Study: NCT02048306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based PR program
Description: The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PR program
Description: The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
Study: NCT00591643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging, Adrenal acans
Description: The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (NP-59)
Description: One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
Study: NCT04504396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study: NCT03101878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ionis AGT-LRx
Description: Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline .9%
Study: NCT01351688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3514
Description: Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
Study: NCT01770938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Effective light-emitting diode therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light-emitting diode therapy
Study: NCT02853279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Description: Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training (CON)
Description: Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
Study: NCT01901666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy
Study: NCT00098826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00319358

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: 600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03365726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress test with trans-esophageal echocardiography
Description: Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored.
Study: NCT04133376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping with nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah containing nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping with nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah containing nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping without nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping without nicotine
Description: Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
Study: NCT03970122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFB-887
Description: IMP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching
Study: NCT02185690

Intervention type: DRUG
Group type: OTHER
Intervention: Binimetinib
Description: Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule.

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 4-6 cycles given intravenously in combination with carboplatin as per standard therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: 4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
Study: NCT02347501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin (Januvia)
Description: Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
Study: NCT00683202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
Study: NCT00005576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody Ch14.18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given IV
Study: NCT02448927

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon aortic valvuloplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter Aortic Valve Implantation
Study: NCT00041496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-207266
Description: White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SB-207266
Study: NCT05067361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ball Exercises
Description: Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ball Exercises
Description: Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
Study: NCT03087032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.